= Emerging. More than 5 years before clinical availability. (26.55%)
= Expected to be clinically available in 1 to 4 years. (39.66%)
= Clinically available now. (33.79%)
MSACL 2020 US : Crawford

MSACL 2020 US Abstract

Topic: Practical Training

Podium Presentation in Room 6 on Wednesday at 16:15 (Chair: Matt Crawford / Deborah French)

Working Smarter Not Harder on Sample Prep

Matthew Crawford (Presenter)

Presenter Bio(s): I am a Scientist at LabCorp for the Mass Spectrometry Research and Development department. I entered the clinical lab space as a technician at LabCorp’s Esoterix Endocrinology and then moved to be a part of the corporate R&D team. My efforts are focused high-throughput small molecule method development, laboratory automation, method validation (CAP, CLIA, and FDA Bioanalytical), and micro sampling evaluation and validation.

Authors: Matthew L. Crawford
Laboratory Corporation of America, Burlington NC


Session Description

With a suite of sample preparation tools at one’s disposal, where does one start? Theory can certainly provide guidance, but practical considerations may a better north star for the clinical laboratory environment. Certain aspects, such as analytical measurement requirements based on defined clinical reference intervals, can be a quick adjudicator for the type of sample preparation needed (i.e. dilutive or concentration approach) but not prescribe the exact procedure. Other practical considerations within the laboratory can include; turnaround time, laboratory/personnel requirements, automation, environmental/health safety, and cost. If not taken into account, one can end up with a sample preparation protocol which is labor intensive and costly. Is that necessary? Can a method be more efficient from a cost and labor perspective and not sacrifice quality? Examples of such considerations and a method development journey that resulted in two possible sample prep protocols, and a comparison of each will be discussed herein.

Take Home Pearls

Goals are to arm one with pragmatic and practical considerations for method development of robust clinical methods along with design and interpretation of fundamental experiments required to provide confidence in sample prep methods.

Financial Disclosure

Board Memberno
IP Royaltyno

Planning to mention or discuss specific products or technology of the company(ies) listed above: